Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | PTGER1 | P34995 | 9/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.56 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585647 | 0.90 | CSNK2A1 (0.52) | HPGDSPTGER1CSNK2A1AMY1ATYR | |
| SCHEMBL5585878 | 0.89 | PTGER1 (0.56) | PTGER1MAPTTBXA2RCYP2C9 | |
| SCHEMBL5585704 | 0.88 | CSNK2A1 (0.68) | HPGDSCSNK2A1AMY1ATYRMEN1 | |
| SCHEMBL5585515 | 0.80 | PTGER1 (0.55) | PTGER1MAPTSMN1; SMN2TBXA2RCYP2C9 | |
| SCHEMBL5585641 | 0.80 | PTGER1 (0.55) | PTGER1TBXA2RCYP2C9 | |
| SCHEMBL5585818 | 0.80 | PTGER1 (0.47) | PTGER1TBXA2RCYP2C9 | |
| SCHEMBL5585748 | 0.80 | PTGER1 (0.54) | PTGER1TBXA2RCYP2C9 | |
| SCHEMBL5585682 | 0.78 | CSNK2A1 (0.62) | HPGDSCSNK2A1AMY1ATYRMEN1 | |
| SCHEMBL5585496 | 0.78 | PTGER1 (0.52) | PTGER1TBXA2RCYP2C9 | |
| SCHEMBL5585539 | 0.77 | KMT2A (0.57) | HPGDSCSNK2A1MEN1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | HPGDS 3401/4885PTGER1 3758/4885CSNK2A1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.